InterShunt Enrolls First Patient in New Heart Failure Study
Innovative procedure aims to ease symptoms and reduce hospitalizations
Newswise — MINNEAPOLIS, June 30, 2025 /PRNewswire/ — InterShunt Technologies, Inc., a medical device company focused on developing minimally invasive treatments for heart failure, has officially kicked off its latest clinical study, the EASE HF2 Early Feasibility Study, which is evaluating a device designed to reduce heart failure symptoms and improve quality of life.
The first U.S. procedure utilizing InterShunt’s technology was performed by Dr. Sitaramesh Emani and the Structural Heart Intervention Team at The Christ Hospital Health Network in Cincinnati, Ohio. “We’re excited to get this study started,” said Dr. Emani. “The first procedure went smoothly, and the patient went home the next day feeling well. It’s an encouraging start, and we’re hopeful this treatment can help many more people.”
The study focuses on patients with heart failure with reduced ejection fraction (HFrEF), a condition where the heart does not pump as well as it should, leading to excessive pressure within the heart. Current treatments do not work for everyone, and this new approach could offer a better option.
The device works by creating a small opening between the heart’s upper chambers to relieve pressure that builds up in heart failure. It uses a mechanical cutting method that avoids scarring and allows the heart to move naturally.
